Almost every AI tool aimed at the NHS is built for clinicians. Frontier Health raised $16M to build for the people behind them.

The London startup announced a $16M seed round led by Atomico, with firstminute capital and XYZ Venture Capital also taking part. It is the first institutional money into the company, founded in 2024.

Frontier Health makes JUNO, an AI agent built not for doctors but for NHS administrative teams, the coordinators who chase test results, rebook missed appointments, and spot patients stuck in a care pathway before a target is breached.

That focus is unusual. Most NHS AI funding has gone to ambient scribing, the tools that transcribe clinical conversations into notes. Tandem Health raised $50mn for that in 2025; TORTUS, Heidi, and Microsoft's Dragon Copilot are chasing the same clinician market. The admin layer that actually governs patient flow has been largely ignored.

Why Atomico moved early

Atomico, which manages $4.7bn and backed Klarna, Supercell, and DeepL, usually waits for more proof before leading a seed. Here it had some.

At East Sussex Healthcare NHS Trust, Frontier says JUNO saved 221 staff days over eight weeks and cut the median time patients spent in the emergency department by nearly 22 per cent. Atomico says it checked the results independently.

“Most enterprise AI is still looking for proof that it works in the real world. Frontier Health already has it, inside one of the most complex and demanding environments on the planet,” said Atomico partner Andreas Helbig, who led the deal.

JUNO operates a screen much as a person would, with the same system permissions, and hands a case to a human when it hits something it does not understand. Frontier says it can be deployed within eight weeks without changes to existing IT.

The Palantir pipeline, and its irony

Founder Rachel Finegold spent six years as Palantir's healthcare lead, working across more than 40 NHS hospitals during the pandemic. “There physically weren't enough administrators to support this integral machinery that needs to happen to keep patients moving,” she said.

She is part of a pattern. Conduct, founded by three other former Palantir staff, raised a large round of its own this week. Ex-Palantir teams are quietly building much of Britain's enterprise AI.

The irony is that Palantir itself is under fire in the NHS. More than half of England's trusts use its software, but the British Medical Association has called for the health service to drop it, and the government is reviewing its £330mn contract. Frontier's pitch, in effect, is the operational value Palantir promised, sold by one of its alumni, without the political baggage.

The bigger question the round raises is why so little money has gone here before. Seven million patients sit on the NHS waiting list, and many delays trace back to admin failures, not clinical capacity. If Frontier's early numbers hold across more trusts, the most overlooked workers in the health service may turn out to be the most fundable.